Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives
Amyotrophic Lateral Sclerosis (ALS) is a highly fatal neurodegenerative disorder characterized by the progressive wasting and paralysis of voluntary muscle. Despite extensive research, the etiology of ALS remains elusive, and effective treatment options are limited. However, recent evidence implicat...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/16/5/590 |
| _version_ | 1797264101364203520 |
|---|---|
| author | Ahmed Noor Eddin Mohammed Alfuwais Reena Noor Eddin Khaled Alkattan Ahmed Yaqinuddin |
| author_facet | Ahmed Noor Eddin Mohammed Alfuwais Reena Noor Eddin Khaled Alkattan Ahmed Yaqinuddin |
| author_sort | Ahmed Noor Eddin |
| collection | DOAJ |
| description | Amyotrophic Lateral Sclerosis (ALS) is a highly fatal neurodegenerative disorder characterized by the progressive wasting and paralysis of voluntary muscle. Despite extensive research, the etiology of ALS remains elusive, and effective treatment options are limited. However, recent evidence implicates gut dysbiosis and gut–brain axis (GBA) dysfunction in ALS pathogenesis. Alterations to the composition and diversity of microbial communities within the gut flora have been consistently observed in ALS patients. These changes are often correlated with disease progression and patient outcome, suggesting that GBA modulation may have therapeutic potential. Indeed, targeting the gut microbiota has been shown to be neuroprotective in several animal models, alleviating motor symptoms and mitigating disease progression. However, the translation of these findings to human patients is challenging due to the complexity of ALS pathology and the varying diversity of gut microbiota. This review comprehensively summarizes the current literature on ALS-related gut dysbiosis, focusing on the implications of GBA dysfunction. It delineates three main mechanisms by which dysbiosis contributes to ALS pathology: compromised intestinal barrier integrity, metabolic dysfunction, and immune dysregulation. It also examines preclinical evidence on the therapeutic potential of gut-microbiota-modulating agents (categorized as prebiotics, probiotics, and postbiotics) in ALS. |
| first_indexed | 2024-04-25T00:23:33Z |
| format | Article |
| id | doaj.art-993e21247c1246d5bc29ab2d22a8b650 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-04-25T00:23:33Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-993e21247c1246d5bc29ab2d22a8b6502024-03-12T16:51:51ZengMDPI AGNutrients2072-66432024-02-0116559010.3390/nu16050590Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future PerspectivesAhmed Noor Eddin0Mohammed Alfuwais1Reena Noor Eddin2Khaled Alkattan3Ahmed Yaqinuddin4College of Medicine, Alfaisal University, Riyadh 11533, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi ArabiaCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi ArabiaAmyotrophic Lateral Sclerosis (ALS) is a highly fatal neurodegenerative disorder characterized by the progressive wasting and paralysis of voluntary muscle. Despite extensive research, the etiology of ALS remains elusive, and effective treatment options are limited. However, recent evidence implicates gut dysbiosis and gut–brain axis (GBA) dysfunction in ALS pathogenesis. Alterations to the composition and diversity of microbial communities within the gut flora have been consistently observed in ALS patients. These changes are often correlated with disease progression and patient outcome, suggesting that GBA modulation may have therapeutic potential. Indeed, targeting the gut microbiota has been shown to be neuroprotective in several animal models, alleviating motor symptoms and mitigating disease progression. However, the translation of these findings to human patients is challenging due to the complexity of ALS pathology and the varying diversity of gut microbiota. This review comprehensively summarizes the current literature on ALS-related gut dysbiosis, focusing on the implications of GBA dysfunction. It delineates three main mechanisms by which dysbiosis contributes to ALS pathology: compromised intestinal barrier integrity, metabolic dysfunction, and immune dysregulation. It also examines preclinical evidence on the therapeutic potential of gut-microbiota-modulating agents (categorized as prebiotics, probiotics, and postbiotics) in ALS.https://www.mdpi.com/2072-6643/16/5/590amyotrophic lateral sclerosisneurodegenerationmicrobiotagut-brain axisgut modulationdysbiosis |
| spellingShingle | Ahmed Noor Eddin Mohammed Alfuwais Reena Noor Eddin Khaled Alkattan Ahmed Yaqinuddin Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives Nutrients amyotrophic lateral sclerosis neurodegeneration microbiota gut-brain axis gut modulation dysbiosis |
| title | Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives |
| title_full | Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives |
| title_fullStr | Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives |
| title_full_unstemmed | Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives |
| title_short | Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives |
| title_sort | gut modulating agents and amyotrophic lateral sclerosis current evidence and future perspectives |
| topic | amyotrophic lateral sclerosis neurodegeneration microbiota gut-brain axis gut modulation dysbiosis |
| url | https://www.mdpi.com/2072-6643/16/5/590 |
| work_keys_str_mv | AT ahmednooreddin gutmodulatingagentsandamyotrophiclateralsclerosiscurrentevidenceandfutureperspectives AT mohammedalfuwais gutmodulatingagentsandamyotrophiclateralsclerosiscurrentevidenceandfutureperspectives AT reenanooreddin gutmodulatingagentsandamyotrophiclateralsclerosiscurrentevidenceandfutureperspectives AT khaledalkattan gutmodulatingagentsandamyotrophiclateralsclerosiscurrentevidenceandfutureperspectives AT ahmedyaqinuddin gutmodulatingagentsandamyotrophiclateralsclerosiscurrentevidenceandfutureperspectives |